Our top pick for
Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.
Mersana Therapeutics, Inc is a biotechnology business based in the US. Mersana Therapeutics shares (MRSN) are listed on the NASDAQ and all prices are listed in US Dollars. Mersana Therapeutics employs 83 staff and has a trailing 12-month revenue of around USD$1.7 million.
|Latest market close||USD$23.77|
|52-week range||USD$1.67 - USD$26.64|
|50-day moving average||USD$19.4306|
|200-day moving average||USD$17.2893|
|Wall St. target price||USD$26.8|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||USD$-1.116|
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|1 week (2021-01-11)||29.68%|
|1 month (2020-12-18)||-7.44%|
|3 months (2020-10-16)||32.94%|
|6 months (2020-07-17)||5.22%|
|1 year (2020-01-17)||195.28%|
|2 years (2019-01-18)||540.70%|
|3 years (2018-01-18)||52.47%|
|5 years (2016-01-15)||N/A|
|Revenue TTM||USD$1.7 million|
|Gross profit TTM||USD$-12,917,000|
|Return on assets TTM||-19.68%|
|Return on equity TTM||-36.51%|
|Market capitalisation||USD$1.2 billion|
TTM: trailing 12 months
There are currently 6.7 million Mersana Therapeutics shares held short by investors – that's known as Mersana Therapeutics's "short interest". This figure is 19% up from 5.6 million last month.
There are a few different ways that this level of interest in shorting Mersana Therapeutics shares can be evaluated.
Mersana Therapeutics's "short interest ratio" (SIR) is the quantity of Mersana Therapeutics shares currently shorted divided by the average quantity of Mersana Therapeutics shares traded daily (recently around 1.5 million). Mersana Therapeutics's SIR currently stands at 4.4. In other words for every 100,000 Mersana Therapeutics shares traded daily on the market, roughly 4400 shares are currently held short.
However Mersana Therapeutics's short interest can also be evaluated against the total number of Mersana Therapeutics shares, or, against the total number of tradable Mersana Therapeutics shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Mersana Therapeutics's short interest could be expressed as 0.1% of the outstanding shares (for every 100,000 Mersana Therapeutics shares in existence, roughly 100 shares are currently held short) or 0.1219% of the tradable shares (for every 100,000 tradable Mersana Therapeutics shares, roughly 122 shares are currently held short).
Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Mersana Therapeutics.
Find out more about how you can short Mersana Therapeutics stock.
We're not expecting Mersana Therapeutics to pay a dividend over the next 12 months.
Over the last 12 months, Mersana Therapeutics's shares have ranged in value from as little as $1.67 up to $26.64. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Mersana Therapeutics's is 2.4159. This would suggest that Mersana Therapeutics's shares are significantly more volatile than the average for this exchange and represent a higher risk.
Mersana Therapeutics, Inc., a clinical stage biopharmaceutical company focusing on the development of antibody drug conjugate (ADC) for cancer patients with unmet need. The company develops Dolaflexin, a platform, which is used to generate a pipeline of proprietary ADC product candidates to address patient populations that are not amenable to treat with traditional ADC-based therapies. Its lead product candidate is XMT-1536, a Dolaflexin ADC targeting NaPi2b that is in Phase I clinical trial for the treatment of patients with ovarian cancer, non small cell lung cancer, and other orphan indications. Mersana Therapeutics, Inc. has a strategic research and development partnerships with Merck KGaA and Asana BioSciences, LLC for the development of ADC product candidates utilizing Fleximer. The company was formerly known as Nanopharma Corp. and changed its name to Mersana Therapeutics, Inc. in November 2005. Mersana Therapeutics, Inc. was incorporated in 2001 and is based in Cambridge, Massachusetts.
Everything we know about the CDT Environmental Technology Investment Holdings Limited IPO, plus information on how to buy in.
Everything we know about the Viant Technology Inc IPO, plus information on how to buy in.
Steps to owning and managing EVGN, with 24-hour and historical pricing before you buy.
Steps to owning and managing ETL, with 24-hour and historical pricing before you buy.
Steps to owning and managing EQBK, with 24-hour and historical pricing before you buy.
Steps to owning and managing EIGI, with 24-hour and historical pricing before you buy.
Steps to owning and managing ELTK, with 24-hour and historical pricing before you buy.
Steps to owning and managing DNKN, with 24-hour and historical pricing before you buy.
Steps to owning and managing DKL, with 24-hour and historical pricing before you buy.
Steps to owning and managing DMAC, with 24-hour and historical pricing before you buy.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.